Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
Cash Investment Expected to Significantly Advance Fluidigm’s Mission through New Growth Initiatives and Cost Structure Optimization SOUTH SAN FRANCISCO, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today urged Fluidigm stockholders to vote “FOR” ALL proposals
View HTML
Toggle Summary Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY SOUTH SAN FRANCISCO, Calif. , March 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), today announced that leading independent proxy advisory firms Institutional Shareholder Services
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December
View HTML
Toggle Summary Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies
Collaboration Enables Further Expansion of Mass Cytometry in the Middle East SOUTH SAN FRANCISCO, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today
View HTML
Toggle Summary Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special Meeting”) at which Fluidigm stockholders will
View HTML
Toggle Summary Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.
Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions Dr. Michael Egholm , Former CTO of Danaher Life Sciences, to Assume Role of CEO and Join Board of Directors Following Close; Alex Kim , Former
View HTML
Toggle Summary Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021
Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth quarter and 12% for full year as new Biomark OEM and CyTOF XT instruments  contributed to revenue SOUTH
View HTML
Toggle Summary Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company’s Biomark Platform Detects Omicron Variant of COVID-19
No Published Viral Mutations to Date, Including Omicron Variant, Meaningfully Impact the Regions of the Viral Genome Targeted by the Assay SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
View HTML
Toggle Summary Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite , President and CEO, and Vikram Jog, Chief
View HTML
Toggle Summary Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost
Streamlines Operations to Reduce Hands-On Time, Accelerate Results Broad Menu of Applications with Automated Workflow Providing Sample-to-Answer Solutions on a Single Platform SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative
View HTML